Paediatric Drug Development and Formulation Design-a European Perspective

Area of Science:

• Pharmaceutical Sciences
• Pediatric Pharmacology
• Regulatory Science

Background:

• Children often receive adult medications off-label due to a lack of licensed pediatric drugs and suitable formulations.
• Off-label and unlicensed drug use in children increases the risk of adverse events.
• Global initiatives are crucial for developing safer and more effective medicines for pediatric populations.

Purpose of the Study:

• To review the European Union's challenges and achievements in pediatric drug development.
• To focus on regulatory advancements and formulation design for pediatric medicines.
• To assess the impact of the European Paediatric Regulation and related guidelines.

Main Methods:

• Analysis of the European Paediatric Regulation (2007) and its requirements for Paediatric Investigation Plans.
• Examination of the Guideline on the Pharmaceutical Development of Medicines for Paediatric Use (2013).
• Discussion of key aspects including novel formulations, excipient safety, and patient acceptability.

Main Results:

• The European Paediatric Regulation mandates early consideration of pediatric needs in drug development.
• The guideline enforces rigorous standards for pharmaceutical design, including dosage forms, excipients, and administration devices.
• Novel formulations like mini-tablets and orodispersible films are being explored to improve pediatric drug delivery.

Conclusions:

• EU regulations have significantly advanced pediatric drug development, promoting safer and more appropriate medicines.
• Compliance with guidelines ensures better formulation design, excipient safety, and patient-centered approaches.
• Continued focus on regulatory compliance and innovative formulations is essential for improving pediatric pharmacotherapy.